REGENCY Yields Positive Results for Obinutuzumab in LN
#nephrology #rheumatology #lupusnephritis #lupus Results of the REGENCY phase 3 trial published in the New England Journal of Medicine demonstrated that obinutuzumab paired with standard therapy had greater efficacy than standard therapy alone in treating lupus nephritis. Lead investigator Richard Furie, MD, discussed the study and the history of obinutuzumab with Nephrology Times.
▶︎
Obinutuzumab in Lupus Nephritis - REGENCY - Prof. Dr. Brad Rovin, Prof. Dr. Ana Malvar
▶︎
The Next-Wave in IgA Nephropathy: Your Guide to B-Cell Developments at ASN Kidney Week
▶︎
2026 Update: What to Do When Lupus Nephritis Biologics Fail
▶︎
Doctor reveals undisclosed risks of COVID-19 vaccine
▶︎
But what is quantum computing? (Grover's Algorithm)
▶︎
Drugs for Heart Failure
▶︎
Antineoplastic Agents | Clinical Medicine
▶︎
Cancer and metabolism
▶︎
Felzartamab Enters Phase 3 Trial for PMN
▶︎
Evolution of Cardiac Diagnostics: A New Era with AI-Powered FFR-CT
▶︎
Posture, Bone Density & Muscle: A Stanford Doctor Destroys Aging Myths Most People Believe
▶︎
What Alcohol Does to Your Body, Brain & Health
▶︎
Enhanced Belimumab Results in BLISS-LN Subgroup Analysis
▶︎
The Science & Treatment of Obsessive Compulsive Disorder (OCD)
▶︎
Vascular Surgeon: What Really Causes Clogged Arteries | Dr. Lily Johnston
▶︎
CNS Infections | Clinical Medicine
▶︎
Top 10 SUPER FOODS That Can Heal Your KIDNEYS
▶︎
IgA Nephropathy: The Kidney Diet Plan Doctors Recommend
▶︎
High CAC Score: What It Means and Exactly What to Do Next
▶︎